echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Researchers have published the latest results in the development of new crown drugs in Science

    Researchers have published the latest results in the development of new crown drugs in Science

    • Last Update: 2021-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Xinhua Chengdu, February 19 (Reporter He Weiqing) reporters learned from Sichuan University on the 19th, Sichuan University Huaxi Hospital Biological Therapy National Key Laboratory jointly
    Kunming Animal Research Institute, published online in Science on the same day entitled "SARS-CoV-2 Mpro resentors with antiviral activity in a transgenic mouse model" research paper. Experimental data on the SARS-CoV-2 infected mouse model of the new crown Mpro inhibitor were publicly reported for the first time.
    it is understood that SARS-CoV-2 main protease (Mpro) play a key role in the replication of the new coronavirus, and its unique cutting points are different from the human protease, so it is considered an ideal target for the development of anti-neoproviral drugs. The study was first designed with rational drugs and synthesized into 32 new structural small molecule compounds containing fragments of bicyclic proline, which effectively inhibit SARS-CoV-2Mpro activity (IC50:7.6-748.5nM) in-body. The
    team selected MI-23, an enzyme-suppressing representative molecule with the highest activity, and by analyzing its crystal structure with the Mpro complex, they clarified the interaction patterns between inhibitors and Mpro, which is a good explanation of the highly active structural basis of these compounds, which is also consistent with the team's original molecular design ideas.
    After evaluating the anti-SARS-CoV-2 virus activity, pharmacogenetic properties and safety of rats at the in vitro cell level of this series of compounds, the research team finally selected two small molecular compounds (MI-09, MI-30) with high activity and good pharmacogenetic properties and safety to carry out in vivo antiviral activity testing. In
    mouse models infected with SARS-CoV-2, oral or abdominal injections of MI-09 or MI-30 significantly reduced lung viral load and lung pathological damage.
    The study reported a series of highly active new structural new coronavirus Mpro small molecule inhibitors, and elaborated the agents and antiviral effects of these inhibitors at the molecular, cell and animal levels, confirming the potential of these compounds to develop anti-SARS-CoV-2 virus drugs in terms of pharmacological properties and safety.
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.